The DAC is transported into the cell and then phosphorylated by deoxycytidine kinase (DCK) to the active metabolite 5‐aza‐dCTP, which incorporates into DNA during DNA replication to form a covalent complex with DNMTs, thereby inhibiting their activities followed by a reduction of DNA methylation, and consequently inducing anti‐leukemia effects.9 However, increasing clinical studies have found that resistance to such drug can develop during treatment and lead to treatment failure. Here, DCK is linked to leukemia.